Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.57 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL28023686 | 0.90 | XDH (0.57) | MMP3MEN1ESR1KMT2AXDH | |
| SCHEMBL27787243 | 0.87 | CLK4 (0.63) | XDHSLC22A12PTPN5CLK4PGR | |
| SCHEMBL1029016 | 0.86 | HSD17B1 (0.58) | ESR1XDHSLC22A12HSD17B1HSD17B2 | |
| SCHEMBL30165928 | 0.86 | HSD17B1 (0.58) | ESR1XDHSLC22A12HSD17B1HSD17B2 | |
| SCHEMBL21189130 | 0.85 | CLK4 (0.57) | MMP3XDHSLC22A12PTPN5CLK4 | |
| Hydrochloric Acid SCHEMBL28007259 | 0.85 | CLK4 (0.61) | XDHSLC22A12PTPN5CLK4PGR | |
| SCHEMBL2154026 | 0.85 | CLK4 (0.65) | XDHSLC22A12PTPN5CLK4PGR | |
| SCHEMBL29425207 | 0.83 | GABRG2 (0.61) | XDHSLC22A12PTPN5CLK4MMP12 | |
| SCHEMBL270874 | 0.83 | GABRG2 (0.61) | XDHSLC22A12PTPN5CLK4MMP12 | |
| SCHEMBL29511815 | 0.82 | XDH (0.56) | XDHSLC22A12PTPN5CLK4MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028773-B | Diester compounds of PPAR protein activator | 南昌弘益科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| CN-112028773-A | Diester compound of PPAR protein activator | 南昌弘益科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3455328-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| CN-1208403-A | Compounds | BRITISH ASTRA PHARMACEUTICALS (GB) | 1999-02-17 | — | — | CN | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
| US-5262052-A | Separation of polycyclic aromatic hydrocarbons | BRIGHAM YOUNG UNIVERSITY (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | MMP3 809/4885MEN1 3426/4885ESR1 4780/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | MMP3 809/4885MEN1 3426/4885ESR1 4780/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | MMP3 3/4885MEN1 2722/4885ESR1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.